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INTRODUCTION 
 
          Portal hypertension  is  defined as  portal pressure gradient of more 
than 6 mm Hg. The hypertensive portal vein is decompressed by diverting 
up to 90% of  the portal flow through portasystemic collaterals back to the 
heart resulting  in enlargement of these vessels. These vessels are 
commonly located at the  gastro esophageal junction where they lie 
subjacent to the mucosa and present as  gastric and esophageal varices.  
Duodenum , rectum , retroperitoneum are the  other important  sites where 
significant collaterals form due to portal  hypertension.  However, due to 
their higher resistance and increased portal  venous inflow, these collaterals 
are unable to decrease the hypertension. 
 
Demonstration of the existence and extent of portosystemic 
collaterals is  important in the management of patients with portal 
hypertension. The reported  prevalence of esophageal varices in cirrhotic 
patients is variable with figures  ranging  between 24% and 80%, with a 
mean of about 60% 1: The prevalence  of varices seems to be related to the 
degree of liver dysfunction, 30% for  compensated patients and of 60% for 
decompensated patients 2 ,3. Because of  this variability, it has been 
recommended that all patients with cirrhosis should  be evaluated by 
endoscopy to ascertain the presence of portal hypertension.4,5. 
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The risk of developing varices in patients who’s  initial endoscopy  
is negative for varices is about 5- 8 % per year  6,8. The rate of increase of  
variceal  size from small to large is not well defined. Those with small 
varices  tend to develop large varices by about 45% in 2 years time(9,10).  
     
Variceal hemorrhage occurs in 25 to 40 percent of patients with 
cirrhosis which  accounts for 10–30% of all cases of upper gastrointestinal   
bleeding . (11) .The annual incidence of variceal bleed in a non bleeder is 
about  4%  12, 13 . Survivors of an episode of active bleeding have a 70 
percent risk  of recurrent hemorrhage within one year of the bleeding 
episode 14 
 
The mortality resulting from any bleeding episode may range from   
< 10% in  well compensated cirrhotic patients with Child–Pugh grade A to        
> 70% in those in the advanced Child–Pugh C cirrhotic stage.(15- 18) .The 
risk of re-bleeding is high, reaching 80% within 1 year .In view of the 
relatively high rate of bleeding from esophageal varices and the high 
associated mortality, an  important goal of management of patients with 
cirrhosis is the primary prevention of variceal hemorrhage.  
 
There are several medical and surgical modalities available for 
primary prophylaxis of variceal hemorrhage. These therapies are aimed at 
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achieving  either by decreasing portal hypertension (eg, beta blockers, 
surgical portal decompression, or transjugular intrahepatic shunt.), or by 
directly treating the varices themselves (eg, variceal ligation). Beta 
blockers are effective in primary prevension of variceal bleed but this 
Randomized trials and meta-analyses show that beta-blockers reduce the 
number of bleeding events when used as primary prevention in esophageal 
varices.19.     However this treatment is not free from side effects.(20, 21). 
                 
The current recommendations are that follow-up endoscopy  should 
be performed at 2 to 3-year intervals in compensated patients with no  
varices and at 1- to 2-year intervals in compensated patients with small 
varices.22, 23   
 
Once large varices have developed, there is no need for further 
follow-up endoscopy; at this stage the patients should be treated to prevent 
bleeding. The prevalence of large varices is only about 9- 36%  in non 
bleeders. These recommendations imply a considerable burden of 
endoscopies and related costs; they require that patients repeatedly undergo 
an unpleasant procedure, even though up to 50% of them may still not have 
developed esophageal varices 10 years after the diagnosis of cirrhosis.24 . 
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Therefore, these guidelines might not be ideal for clinical practice. 
This inference is supported by recent studies from the United States and 
Italysuggesting that the guidelines are not being fully adopted. 25, 26 . 
Moreover, the guidelines were based largely on studies of patients with 
cirrhosis due to viral hepatitis or alcohol abuse; accordingly, it is unclear to 
what extent the guidelines may apply to patients with other causes of portal 
hypertension.  
 
To reduce the number of unnecessary endoscopies in patients with  
cirrhosis but without varices, several studies have evaluated possible  
noninvasive markers of esophageal varices in patients with  
cirrhosis.27-33 . The conclusion from most of these studies is that by 
selecting patients for  endoscopic screening based on a few laboratory 
and/or ultrasonographic  variables , usually the platelet count and the 
diameter of the portal vein , an  appreciable number of endoscopies may be 
avoided, while keeping the rate of  undiagnosed varices, which are at risk 
of bleeding, acceptably low . However,  the predictive accuracy of such 
noninvasive markers is still considered to be  unsatisfactory, and none of 
them has been recommended for use in clinical  practice so far.34  
A recent inclusion in this scenario is the blood ammonia  level predicts the 
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esophageal varices and large spontaneous porto systemic  shunt  
presence. 30 
      
Studies combining venous ammonia and other non invasive 
predictors on  Indian patients are limited . Such predictive factors may be 
expected to vary in  different populations because of differences in the 
etiologies of liver cirrhosis,  severity of liver disease. Therefore this  study 
was conducted to evaluate the  utility of  blood ammonia,  spleen size and 
platelet count as a predictor of   esophageal varices and large spontaneous 
porto systemic shunt presence.  
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LITERATURE REVIEW 
 
PORTAL HYPERTENSION 
 
The natural history of cirrhosis can be divided into a preclinical 
phase and a  subsequent clinical phase. The preclinical phase is usually 
prolonged over  several years; once clinical events such as the development 
of ascites, encephalopathy, and variceal bleeding occur, the remaining 
course of the  disease is much shorter and usually fatal. Portal hypertension 
is crucial in the  transition from the preclinical to the clinical phase of 
cirrhosis ;  it is a contributive mechanism of ascites and encephalopathy 
and a direct cause of  variceal bleeding and bleeding-related death. 
 
Portal hypertension in cirrhosis is determined by an increase in both  
intrahepatic vascular resistance and portal venous inflow. Intrahepatic  
vascular resistance is caused by the architectural distortion of the liver  
resulting from fibrosis and by increased sinusoidal tone. Portal venous 
inflow  results from a combination of an hyper dynamic circulatory state 
and increased plasma volume. In response to the increased portal pressure, 
collateral circulation develops by the opening of preexisting vascular 
channels and possibly by neoformation of vessels. From a clinical 
standpoint, esophagogastric varices are the most important collateral 
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vessels: they tend to increase in size with the increase of portal pressure 
and rupture when wall tension exceeds a critical value. 
 
Knowledge of the natural history of portal hypertension may help in 
making important decisions about the diagnosis, monitoring and follow-up, 
and treatment of patients with this condition.  
 
Portal hypertension is classified accoding to the localization of the 
flow resistance  as pre hepatic , intra hepatic and post hepatic blocks. The 
intra hepatic form is sub divided as presinusoidal , sinusoidal and post 
sinusoidal portal hypertension 
 
NON – PARENCHYMATOUS PORTAL HYPERTENSION 
 
1. PREHEPATIC PORTAL HYPERTENSION 
2. INTRAHEPATIC PORTAL HYPERTENSION 
A. PRESINUSOIDAL 
  PARENCHYMATOUS PORTAL HYPERTENSION 
B. SINUSOIDAL  
C. POST SINUSOIDAL BLOCK 
3. POST HEPATIC PORTAL HYPERTENSION 
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ESOPHAGEAL VARICES 
 
Bleeding from ruptured esophagogastric varices is the most severe  
complication of cirrhosis and is the cause of death in about one third of  
cirrhotic patients.  Varices form when the HVPG exceeds 10 mm Hg and  
usually do not bleed unless the hepatic venous pressure gradient (HVPG)  
exceeds 12 mm Hg 45. Gastroesophageal varices have two main inflows,  
the first is the left gastric or coronary vein. The other major route of inflow 
is  the splenic hilus, through the short gastric veins.  
 
Four distinct zones of venous drainage at the gastroesophageal 
junction are particularly relevant to the formation of esophageal varices. 
 The gastric zone, which extends for 2 to 3 cm below the gastroesophageal 
junction, comprises veins that are longitudinal and located in the 
submucosa and lamina propria. They come together at the upper end of the 
cardia of the stomach and drain into short gastric and left gastric veins. The 
palisade zone extends 2 to 3 cm proximal to the gastric zone into the lower 
esophagus. The perforating veins in the palisade zone do not communicate 
with periesophageal veins in the distal esophagus. The palisade zone is the 
dominant watershed area between the portal and systemic circulations. 
More proximal to the palisade zone in the esophagus is the perforating 
zone, where there is a network of veins. These veins are less likely to be 
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longitudinal and are termed perforating veins because they connect the 
veins in the esophageal submucosa and the external veins.  
 
The truncal zone, the longest zone, is approximately 10 cm in length,  
located proximally to the perforating zone in the esophagus, and usually  
characterized by four longitudinal veins in the lamina propria. Veins in the 
palisade zone in the esophagus are most prone to bleeding  because no 
perforating veins at this level connect the veins in the submucosa  with the 
periesophageal veins. Varices in the truncal zone are unlikely to  bleed. 
The periesophageal veins drain into the azygous system, and as a  result, an 
increase in azygous blood flow is a hallmark of portal hypertension.  
 
GASTRIC VARICES  
 
The fundus of the stomach drains through short gastric veins into the 
splenic  vein. In the presence of portal hypertension, varices may therefore 
form in the  fundus of the stomach. Splenic vein thrombosis usually results 
in isolated  gastric fundal varices. Because of the proximity of the splenic 
vein to the renal  vein, spontaneous splenorenal shunts may develop and 
are more common in  patients with gastric varices than in those with 
esophageal varices. The overall  prevalence of gastric varices varies among 
studies, with figures ranging from  10% to more than 50%.46,47.  
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Gastric varices are classified according to sarin et al. 47  About 70% 
of the patients with gastric varices GOV 1, 21% had GOV 2, 6.7% had 
IGV 1 and  1.4% had IGV 2. Gastric varices are significantly more 
common in cirrhotic  patients with a history of variceal bleeding than in 
those who have not bled,  perhaps indicating that gastric varices develop at 
a more advanced stage of portal hypertension.Hemodynamic studies in 
patients with large gastric varices  have demonstrated a lower portal 
pressure, large gastrorenal shunts, and less  risk of hemorrhage but a 
somewhat greater likelihood of portosystemic  encephalopathy. The overall 
incidence of bleeding from gastric varices is  between 3% and 30%.47.  
 
Varices involving the fundus, were the cause of  bleeding in 67% of 
all patients bleeding from gastric varices. Gastric varices  tended to bleed 
less frequently but more severely than esophageal varices. 
 
 
PORTAL HYPERTENSIVE GASTROPATHY  
 
Portal hypertensive gastropathy (PHG) is a collective term that 
defines an  array of diffuse macroscopic lesions observed in the gastric 
mucosa of  patients with portal hypertension. A classification of this entity 
has been  developed  and its reproducibility has been thoroughly evaluated 
48 .This  classification distinguishes a mild form (when a mosaic like 
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pattern is present)  and a severe form (when multiple red signs or black-
brown spots are present).  
 
The prevalence of PHG in reported series is extremely variable (7%–
98%), The prevalence was relatively low (56%) in patients with a new 
diagnosis of  cirrhosis, higher (75%) in patients with a previous diagnosis 
of cirrhosis and  no prior bleeding, and even higher (91%) in patients with 
a previous variceal  bleeding episode with current or prior sclerotherapy. 
 
Thus, PHG shows a strong correlation with the duration of cirrhosis 
and the  severity of portal hypertension, whereas the correlation with the 
degree of  liver dysfunction is weak. The endoscopic appearance of PHG is 
stable in  some patients  and varies with time in most, showing steady 
deterioration or  sustained improvement in about one fifth of the patients 
each, and  fluctuations, with transition from mild to severe and vice-versa 
on sequential  endoscopies, in about one fourth of patients. Bleeding from 
PHG can be acute  or chronic. Endoscopically verified acute bleeding from 
PHG occurs  in 2.5%  of  patients  and chronic bleeding occurs in 12% of 
patients.  
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GASTRIC ANTRAL VASCULAR ECTASIA (GAVE) 
 
GAVE ,also known as watermelon stomach is characterised by red 
patches or  spots in either a diffuse or linear array in the antrum of the 
stomach , which  can result in significant blood loss and leads to chronic 
iron deficiency anemia  Its etiology is  unclear. Vasoactive substances may 
play an important role in the  etiology of vascular ectasia. Neuroendocrine 
cells containing vasoactive  intestinal peptide and 5-hydroxtryptamine have 
been found close to the vessels  in the lamina propria of resected specimens 
from GAVE patients .So, these  mediators may be responsible for the 
vasodilatation and thus the propensity to  bleed .GAVE in cirrhotic patients 
may be explained by the shunting of blood  and altered metabolism of 
vasoactive substances in the presence of liver disease  GAVE have  several 
disease association as primary biliary cirrhosis , connective  tissue disease 
etc. More than 70% of patients with GAVE syndrome do not have  
cirrhosis or portal hypertension .  
 
In the setting of cirrhosis, GAVE syndrome can be difficult to 
differentiate from PHG.   Both conditions are diagnosed endoscopically as 
collections of discrete red spots of ectatic vessels arranged in stripes along 
the antral rugal folds; however, the red spots of PHG appear in a 
background of  mucosal mosaic appearance, but the mucosa underlying 
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GAVE is normal .  Histologically , vascular ectasia in GAVE are seen in 
the mucosa associated with fibrin thrombi ,fibrohylinosis and spindle cell 
proliferation. 
 
PORTAL HYPERTENSIVE  INTESTINAL VASCULOPATHY 
 
Portal hypertensive colopathy was defined endoscopically in patients 
with  vascular ectasia, redness  and  blue vein .Vascular ectasia was further 
classified into two types: type 1, solitary vascular ectasia ; and type 2, 
diffuse  vascular ectasia.  As Child-Pugh class worsens and platelet count 
decreases,  the prevalence of portal hypertensive colopathy increases in 
patients with  liver cirrhosis. Colonoscopic examination is needed in these 
patients,  especially those with worsening Child-Pugh class and decreasing 
platelet  count, to prevent complications, such as lower gastrointestinal 
bleeding. 
 
PORTAL HYPERTENSIVE ENTEROPATHY (PHE) 
 
PHE  is  part of the spectrum of congestive gastroenteropathy .Its 
incidence  doesn't correlate with the Child-Pugh score or with prior 
sclerotherapy.    Circulating hormonal vasodilators from intestinal origin 
such as glucagon and  nitric oxide elevate portal venous pressure 
aggravates noxious injury of the  mucosa in rats with portal hypertension. 
14 
 
The important histologic features in the  portal hypertensive patients 
include edema of the lamina propria, fibromuscular  proliferation, a 
decreased villous/crypt ratio, and thickened muscularis mucosae.   
 
The clinical implication of these changes is the increased chance of 
occult  gastrointestinal blood loss. PHE is usually asymptomatic; massive  
hemorrhage has only rarely been described. The spectrum of portal 
hypertensive  enteropathy varies from protein loosing enteropathy,altered 
intestinal motility,  bacterial overgrowth and malabsorption and intestinal 
lymphagiectasia.  
 
CLINICAL FEATURES OF PORTAL HYPERTENSION 
SYMPTOMS  
 
Hematemesis or melena (gastroesophageal variceal bleeding or 
bleeding from  portal gastropathy) Mental status changes such as lethargy, 
increased irritability, and altered sleep  patterns (presence of portosystemic 
encephalopathy) 
 
Increasing abdominal girth (ascites formation) 
 
Abdominal pain and fever (spontaneous bacterial peritonitis [SBP], 
which also presents without symptoms) 
 
Hematochezia (bleeding from portal colopathy) 
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Physical examination 
 
The signs of portosystemic collateral formation include the 
following: 
 
Dilated veins in the anterior abdominal wall (umbilical epigastric 
vein shunts) 
 
Venous pattern on the flanks (portal-parietal peritoneal shunting) 
 
Caput medusa (tortuous collaterals around the umbilicus) 
 
RECTAL HEMORRHOIDS 
 
Ascites - Shifting dullness and fluid wave (if significant amount of 
ascitic fluid  is present)  
 
Paraumbilical hernia 
Venous hum 
Signs of liver disease include the following: 
Ascites 
Jaundice 
Spider angiomas 
Gynecomastia 
Dupuytren contracture 
Muscle wasting 
Palmar erythema 
Asterixis 
Testicular atrophy 
Splenomegaly 
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Hepatomegaly 
Signs of hyperdynamic circulatory state include the following: 
Bounding pulses 
Warm, well-perfused extremities 
Arterial hypotension 
 
INVESTIGATION OF PORTAL HYPERTENSION 
 
BLOOD INVESTIGATIONS 
 
Liver function tests – to assess severity of the liver disease; reversal 
of albumin : globulin ratio indicates decompensation. 
 
Prothrombin time   - assess coagulation abnormality 
 
Viral hepatitis serologies   
 
Platelet count    -   value of < 150000/mm3 indicates thrombocytopenia. 
 
Antinuclear antibody, antimitochondrial antibody, antismooth muscle 
antibody 
 
Iron indices 
 
Alpha1-antitrypsin deficiency 
 
Ceruloplasmin, 24-hour urinary copper - To be considered only in 
individuals aged 3-40 years who have unexplained hepatic, neurologic, or 
psychiatric disease 
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IMAGING STUDIES  
ULTRASONOGRAPHY 
 
 Ultrasound examination of the liver with Doppler study of the 
vessels has been  used widely to assess patients with portal hypertension. 
Features suggestive of  portal hypertension on ultrasonography include 
splenomegaly, portosystemic  collateral vessels, reversal of the direction of 
flow in the portal vein  (hepatofugal flow)  , portal vein diameter greater 
than 11 mm and the absence  of respiratory variations in the splenic and 
mesenteric veins.  
 
 Ultrasound examination can detect thrombosis of the portal vein, 
which appears as nonvisualization or cavernous transformation of the 
portal vein; the latter finding indicates an extensive collateral network in 
place of the portal vein. Splenic vein thrombosis also can be demonstrated.  
 
PORTAL VEIN DOPPLER  
 
Portal blood flow can be measured by Doppler ultrasonography, 
which is the  easiest research method for detecting postprandial increases 
in splanchnic blood  flow. Although Doppler ultrasonography is clinically 
useful in the initial evaluation of portal hypertension, the technique is not 
widely used to provide  quantitative assessments of the degree of portal 
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hypertension. Pulsed Doppler  Ultrasound was used to analyze hepatic 
artery wave forms near the porta  hepatis.  
 
The Resistive Index (RI) = [pcak systolic frequency shift (A) –  
minimum diastolic frequency shift (B)] / [peak systolic frequency shift (A)] 
has  been calculated from this information. Using a cut off of greater than 
0.77 this  index has a sensitivity, specificity and overall accuracy of 68%, 
70% and 69%  respectively. portal blood flow velocity was found to 
correlate only with the  presence and size of esophageal varices. The 
Congestion Index of the portal  vein (derived from the ratio between the 
cross-sectional area of the portal vein  and the mean velocity of portal 
flow) was significantly different in most  clinical, biochemical and 
endoscopic subgroups and was correlated with liver  function, presence and 
size of varices, and presence and degree of red  signs.conjetion index of 
>0.1 are associated with portal hypertension with  sensitivity and 
specificity of about 95%.  
 
BARIUM STUDIES 
 
Oesophageal varices appears as filling defects with a smooth contour 
in the  lower third of the esophagus. Uphill and downhill varices can be 
clearly demonstrated with barium studies. Patients with portal hypertensive  
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gastropathy had thickened gastric folds, which had a mean thickness of 
10 mm.  The thickened folds had a nodular appearance with undulating 
contours and  indistinct borders which is somewhat different from those of 
gastric varices,  which classically appear as multiple rounded submucosal 
nodules or as  serpentine folds in the gastric fundus.  
 
COMPUTED TOMOGRAPHY 
 
Computed tomography (CT) is useful for demonstrating many 
features of portal hypertension, including abnormal configuration of the 
liver, ascites, splenomegaly, and collateral vessels .Detection of varices 
may be an emerging indication for CT. Diagnosis of fundal varices by 
multidetector row CT (MDCT) is at least as accurate as endoscopic 
ultrasonography. CT is especially helpful in distinguishing submucosal 
from perigastric fundal varices  and is considered a less invasive alternative 
to conventional angiographic portography in assessing portosystemic 
collaterals. At present, however, CT is not a recommended screening 
method for detecting large esophageal varices, but it may be a cost-
effective  method of screening for varices and preferred to endoscopy by 
patients. 
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MAGNETIC RESONANCE IMAGING 
 
Gadolinium-enhanced magnetic resonance imaging  can be used to 
measure and azygous blood flow, which is increased in patients with portal 
hypertension.  MRI provides excellent detail of the vascular structures of 
the liver and can detect portal venous thrombosis and spleen stiffness in 
patients with portal hypertension, but the role of MRI in the assessment of 
portal hypertension requires further study. MRI can accurately assess the 
stiffness of even fatty livers. 
 
ENDOSCOPIC ULTRASONOGRAPHY 
 
Endoscopic ultrasound examination using radial or linear array ech 
endoscopes or endoscopic ultrasound mini-probes passed through the 
working channel of a diagnostic endoscope has been applied as an 
investigational tool in the evaluation of patients with varices. Cross- 
sectional area of varices to identify patients at increased risk of bleeding, 
size of and flow in the left gastric vein, azygous vein, and paraesophageal 
collaterals; changes after endoscopic therapy; and recurrence of esophageal 
varices following variceal ligation all can be assessed by 
endosonography. Endosonography can be combined with endoscopic 
measurement of transmural variceal pressure to allow estimation of 
variceal wall tension, which is a predictor of variceal bleeding 
21 
 
 
TRANSIENT ELASTOGRAPHY  (FibroScan) 
 
 FibroScan (Transient Elastography) is a new device used to measure 
the  elasticity or  stiffness of the liver – the stiffer the liver, the more severe 
the  hepatic fibrosis (scarring). It’s extremely good at picking up mild or 
minimal  disease, and very good at diagnosing cirrhosis, with 90-95% 
accurate positive  predictive value, FibroScan also has other limitations 
that people wanting to  undergo a FibroScan should be aware of; its 
inability to get an effective reading  in patients with significant liver 
inflammation for those who have a pacemaker,  or its inability to diagnose 
moderate fibrosis accurately, and its ineffectiveness  in patients who are 
obese should all be noted.   
 
ESOPHAGO GASTRO DUODENOSCOPY  
 
Upper gastrointestinal endoscopy is the most commonly used 
method to  detect varices. Endoscopic grading of esophageal varices is 
subjective.  Various criteria have been used to try to standardize the 
reporting of  esophageal varices. The best known of these criteria are those 
compiled by  the Japanese Research Society for Portal Hypertension. The 
descriptors  include red color signs, color of the varix, form (size) of the 
varix, and  location of the varix. Red color signs include red “wale” 
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markings, which are  longitudinal whip-like marks on the varix; cherry-red 
spots, which usually are  2 to 3 mm or less in diameter; hematocystic spots, 
which are blood-filled  blisters 4 mm or greater in diameter; and diffuse 
redness. The color of the  varix can be white or blue. The form of the varix 
at endoscopy is described  most commonly.  
 
Esophageal varices may be small and straight (grade I); tortuous and  
occupying less than one third of the esophageal lumen (grade II); or large 
and  occupying more than one third of the esophageal lumen (grade III). 
Varices  can be in the lower third, middle third, or upper third of the 
esophagus. Of all  of the aforementioned descriptors, the size of the varices 
in the lower third of  the esophagus is the most important. The size of the 
varices in the lower third  of the esophagus is determined during 
withdrawal of the endoscope . Small  varices, that is, those occupying less 
than one third of the lumen, are less than  5 mm in diameter, whereas large 
varices are greater than 5 mm in diameter.  
 
Patients with large esophageal varices, Child (or Child-Pugh) class C 
cirrhosis  (see later), and red color signs on varices have the highest risk of 
variceal  bleeding within 1 year. Prophylactic treatment to prevent variceal 
bleeding is  recommended in all patients with large esophageal varices 
irrespective of the  presence or absence of red color signs . 
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ARTERIOGRAPHY 
 
 Injection of contrast medium into the speen either percutaneously or 
by    laparoscopy ensures access to collaterals if  radiological interventions 
are  planned. Indirect splenoportography , hepatic vein phlebography, 
indirect mesentricoportography , transjugular and transhepatic 
splenoportography,  umbilical vein portography  are the some of the 
radiologic methods by which the  collaterals can be ascertained. 
 
MEASUREMENT OF PORTAL PRESSURE 
 
Portal pressure can me measured either by direct or by indirect 
methods. Direct  methods are invasive , cumbersome and rarely used. 
HVPG measurement ,  splenic pulp pressure measurement,  variceal 
pressure , are the indirect methods. HVPG measurement is currently used 
to assess portal pressure. 
 
The HVPG is the difference between the wedged hepatic venous  
pressure (WHVP) and free hepatic vein pressure (FHVP). It has been  
validated as the best predictor for the development of complications of  
portal hypertension. 
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Measurement of the HVPG requires passage of a catheter into the 
hepatic  vein under radiologic guidance until the catheter can be passed no 
further,  that is, until the catheter has been “wedged” in the hepatic vein. 
The  catheter can be passed into the hepatic vein through the femoral vein 
or  using a transjugular venous approach. HVPG is not effective for 
detecting  presinusoidal causes of portal hypertension. HVPG is accurate 
for detecting  only sinusoidal and postsinusoidal causes of portal 
hypertension. 
 
The HVPG is measured at least three times to demonstrate that the 
values are reproducible. Measurement of the HVPG has been proposed for 
the  following indications: (1) to monitor portal pressure in patients taking 
drugs  used to prevent variceal bleeding; (2) as a prognostic marker (3) as 
an end- point in trials using pharmacologic agents for the treatment of 
portal  hypertension; (4) to assess the risk of hepatic resection in patients 
with  cirrhosis; and (5) to delineate the cause of portal hypertension . 
HVPG monitoring is not done routinely in clinical practice because no 
controlled  trials have yet demonstrated its usefulness. 
 
The development of gastroesophageal varices requires a portal 
pressure  gradient of at least 10 mm Hg. Furthermore, a portal pressure 
gradient of at  least 12 mm Hg is thought to be required for varices to 
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bleed; other local  factors that increase variceal wall tension also are 
needed(77) because all  patients with a portal pressure gradient of greater 
than 12 mm Hg do not  necessarily bleed.  
 
Factors that influence variceal wall tension can be viewed  
in the context of the law of Laplace:     
                              T= PR / W  
 
where T is variceal wall tension, P is the transmural pressure 
gradient between the variceal lumen  and esophageal lumen, r is the 
variceal radius, and w is the variceal wall  thickness. When the variceal 
wall thins and the varix increases in diameter  and pressure, the tolerated 
wall tension is exceeded and the varix will rupture. These physiologic 
observations are manifested clinically by the  observation that patients with 
larger varices (r) in sites of limited soft tissue  support (w), with elevated 
portal pressure (P), tend to be at greatest risk for  variceal rupture from 
variceal wall tension (T) that becomes excessive. One  notable site in 
which soft tissue support is limited is at the gastroesophageal  junction. 
The lack of tissue support and high vessel density may contribute  to the 
greater frequency of bleeding from varices at the gastroesophageal  
junction.  
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The law of Laplace also has implications for the relevance of  
pharmacologic therapies aimed at reducing portal pressure. Reductions in  
portal pressure will reduce the variceal transmural pressure gradient,  
thereby reducing the risk that variceal wall tension will become excessive  
and varices will rupture. Clinically, a reduction in the hepatic venous  
pressure gradient to less than 12 mm Hg almost negates the risk of variceal  
hemorrhage. The changes in portal pressure and local variceal factors,  
however, are dynamic and influenced by a number of physiologic (an  
increase in intra-abdominal pressure, meal-induced increases in portal  
pressure), diurnal (circadian changes in portal pressure), and  
pathophysiologic (acute alcohol use) factors, and portal pressure and  
esophageal variceal pressure may vary at different times. 
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AIM  AND OBJECTIVES OF THE STUDY  
 
1. To investigate the diagnostic utility of venous ammonia levels, 
spleen size and  platelet count as non-invasive markers of esophageal 
varices. 
 
2. To correlate these markers with endoscopy findings, ultra sound 
features and Child-  Pugh classification as indices of shunt presence. 
 
3. To evaluate non – invasive markers in predicting  large esophageal 
varices. 
 
4.  To evaluate non – invasive markers  in predicting   Gastric varices  
and large porto systemic collaterals .  
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METHODS 
 
The study included  consecutive patients with liver cirrhosis 
admitted in our institution (Department of Digestive Health and Diseases , 
Government  Peripheral Hospital , Anna nagar , Chennai -102 )  which is a 
major tertiary care  centre for liver diseases .  Ethical Committee approval 
was obtained for this study design. Patients were included in  this study 
after their  willingness to undergo necessary investigations . Informed 
written consent was  taken before the  enrolment in this study.The period of 
study is from December  2008 to January 2011. 
 
Inclusion criteria : 
 
1.Cirrhosis with portal hypertension 
 
EXCLUSION CRITERIA : 
 
1. Previous history of  EST / EVL / Porto systemic shunt surgery 
2. Patients on drugs as a primary prophylaxis for varices 
3. Past history of  variceal bleeding  
4. Hepato cellular carcinoma , detected by ultrasound 
5. Severe co-morbid illness precluding upper GI scopy 
6. History of drug usage which increases blood ammonia level   
7. Intravenous drug abusers 
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8. Acute or chronic renal failure  
 
CLINICAL EVALUATION: 
 
 In all the  patients, the diagnosis of cirrhosis with portal 
hypertension was established by detailed  clinical (spider nevi, 
organomegaly)  etiological (significant alcohol intake ,  blood transfusion, 
tattooing, high risk behaviour etc.) , radiological (portal vein, spleen size) 
Ascites was graded as  none, mild (detectable only on ultrasound), 
moderate (visible moderate  symmetrical abdominal distension) or severe 
(marked abdominal  distension)38 . Hepatic encephalopathy was graded 
from grade 0 to IV, as per  west Heaven criteria. 
 
BLOOD INVESTIGATIONS  : 
 
Includes haemoglobin , WBC count , platelet count , prothrombin 
time , bilirubin (total , direct, indirect ), total protein albumin and globulin , 
alanine  amino transferase , aspartate amino transferase, HBsAg  and   
Anti HCV.  Tests  for auto immune liver disease, haemochromatosis and 
Wilson disease were  done only if clinical situation warrents the study.  
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ULTRASOUND ABDOMEN : 
 
The non-invasive assessment of liver cirrhosis was  performed  to all 
patients by radiologists on the basis of US/US-doppler examinations 
(coarse echo-texture, nodularity presence,  increased caudate/right lobe 
ratio, hypertrophy of the left lobe, characterized by a rounded  inferior 
marginal edge, ) 
 
Spleen measurements of Spleen Longitudinal Diameter (SLD) were 
performed  by postero-lateral scanning with the probe footprint aligned 
along an intercostals  space to provide a longitudinal view of the spleen. 
The patients were asked to breathe slowly, taking long breaths – as varying 
degrees of inspiration and expiration are needed to optimize splenic 
visualization – and to roll on the right side to some extent to aid 
visualization. At this point, the maximum length, i.e., the optically greatest 
overall longitudinal dimension obtained from one of the two poles was 
recorded. Given the high variability in detecting spleen measurements, an 
US value ≥ 110 mm was chosen to correspond to splenomegaly. 
 
ASCITES PRESENCE 
 
When a patient is in a supine position, free fluid tends to accumulate 
in the flanks, particularly the superior end of the right paracolic gutter, and 
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in the pelvis due to the effects of gravity. These areas were carefully 
assessed. Small quantities were sought for around the liver or spleen 
surface and in the Morrison's pouch. 26 
 
PORTAL VEIN DOPPLER  
 
Umbilical vein patency, i.e. diameter ≥ 3 mm, was easily detected 
within the echogenic  ligamentum teres hepatis and was confirmed by color 
Doppler US. SRS was detected by the same method. The direction of blood 
flow in the collateral vein was also analyzed in each patient. The Doppler 
angle used to examine the portal vein was less than 50° in all examinations. 
 
Portal vein enlargement with decreased flow velocity, absence of a 
normal doppler waveform, hepatofugal flow). No evidence of 
hepatocellular carcinoma at the first hepatic  decompensation was detected. 
Renal insufficiency was properly excluded. 
 
ENDOSCOPIC FEATURES 
 
ESOPHAGEAL VARICES 
 
Esophageal varices were graded according to paquet grading system. 
It grades esophageal varices from  I – IV. Patient were further classified as  
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small varices (paquet’s grade I,II ),  large varices ( paquet’s  
grade III , IV).40 
 
PORTAL HYPERTENSIVE GASTROPATHY 
 
 
PHG was assessed according to the NIEC classification .41    Mosaic-
like pattern was  characterized by the presence of small, polygonal areas 
surrounded by a whitish-yellow depressed border. Red-point lesions were 
small, flat, lesions (1 mm in diameter). Cherry-red  spots were red-
coloured, round lesions, slightly protruding into the lumen of the stomach, 
(2 mm in diameter). Black- brown spots were irregularly shaped flat spots, 
black or brown, persistently present after washing. 
 
Ano-rectal varices and Portal Hypertensive Colopathy 
 
For ethical reasons, only patients who presented with a history of 
hematochezia at  entry underwent colonoscopy to track ano-rectal varices 
to differentiate from haemorroides.Portal hypertensive colopathy was 
defined endoscopically in  patients withvascular ectasia  (solitary or 
diffuse), redness, and blue vein42 
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Hepatic encephalopathy grade 
 
Hepatic encephalopathy was graded based on the level of 
consciousness, intellectual  functions, behaviour and neuromuscular 
functions according to West Haven (W-H)  criteria .W-H grade 0 
encephalopathy was ascertained as previously described. 42,43.    
 
Venous ammonia concentration 
 
Venous ammonia levels were quantified according to enzymatic 
determination with  glutamate dehydrogenase using rapid and interference-
free photometry (340 nm), and were  expressed as µ mol / L.Due to reasons 
of safety, blood was  kept chilled and immediately sent to the laboratory 
for determination. Normal  value is between 11- 35µ mol / L. 
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STATISTICAL ANALYSIS 
 
The chi square was used to look for significance of each variables in 
predicting  esophageal , gastric and other large porto systemic collaterals. 
When   confronted with the question of how accurate a parameter was in 
identifying  portosystemic collateral veins presence, the discrimination 
with relative cut-off  or criterion was evaluated using .Sensitivity (true 
positive rate), specificity (true  negative rate) were also weighted for the 
same purpose. Optimal cut-off was  considered the threshold value with the 
best specificity/sensitivity. 
 
To predict the presence of portosystemic collateral veins, hepatic 
decompesation and ascites presence the logistic regression (Enter Method) 
was employed utilizing as independent variables US values for SLD, 
platelets count and blood NH4 concentrations. The same tool was carried 
out to predict the large (II and III grade) EV presence by NH4 
concentrations.  
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RESULTS 
 
Patient characteristics  
 
A total of  61 patients were included in the study. Of those, 
43(70.5%) were  male and 18 were female (29.5%). The symptom patient 
duration in half of the patients falls between 90 – 180 days . Ascites was 
clinically present in 77% of patients. Pedal edema was present in 44% of 
patients. About 37 patients had jaundice at presentation. Spleen was 
palpable in 44 % of patients. 
 
The demographic and clinical characteristics of the patients are 
presented in Table 1.  
 
TABLE 1 :  DEMOGRAPHIC CHARECTERISTICS OF STUDY 
PATIENTS 
 
Sex Frequency Percent 
Male 43 70.5 
Female 18 29.5 
Total 61 100.0 
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TABLE  2 : FREQUENCY OF ASCITES IN STUDY POPULATION 
 
ASCITES Frequency Percent
Absent 14 23.0 
 Present 47 77.0 
 Total 61 100.0 
 
TABLE  3 : PALPABLE SPLEEN 
 
Spleen  Frequency Percent 
 0 34 55.7
1 27 44.3
Total 61 100.0
0 – present ; 1- absent  
 
The majority of the patients were Child-Pugh class C , 29 (47.5%).  
Patients  with child A and B constitutes 14 (23%) & 18 (29.5%) 
respectively. Ascites  was found in 77 % of the patients by ultrasonography 
and clinical examination.  
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TABLE  4 :  CHILD PUGH CLASS IN STUDY POPULATION 
CTP SCORE Frequency Percent 
A 14 23.0 
B 18 29.5 
C 29 47.5 
Total 61 100.0 
 
Esophageal varices were present in 37  patients of which 11 had 
small varices  (18%)  and 26 (42.6%) had large varices . Gastric varices 
was present only in 9  patients. 
 
TABLE 5 : FREQUENCY OF ESOPHAGEAL VARICES IN STUDY 
GROUP  
 
EV Frequency Percent
Valid 
Percent 
Cumulative 
Percent 
Absent 24 39.3 39.3 39.3
Small 11 18.0 18.0 57.4
Large 26 42.6 42.6 100.0
Total 61 100.0 100.0  
EV – Esophageal Varices 
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TABLE  6 : FREQUENCY OF GASTRIC VARICES  
 
 Gastric Varices Frequency Percent
Valid 
Percent 
Cumulative 
Percent 
Absent 55 90.2 90.2 90.2
 Present 6 9.8 9.8 100.0
 Total 61 100.0 100.0  
 
20 patients had (32.8%) portal hypertensive gastropathy along with 
esophageal varices 
 
TABLE 7 : FREQUENCY OF PORTAL HYPERTENSIVE 
GASTROPATHY 
PHG Frequency Percent
Valid 
Percent 
Cumulative 
Percent 
Absent 41 67.2 67.2 67.2
 Present 20 32.8 32.8 100.0
 Total 61 100.0 100.0  
 
 
Large spontaneous porto systemic shunts were detected by color dopper in  
4  patients .  
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TABLE 8 : FREQUENCY OF LARGE SPONTANEOUS SHUNTS 
(LSS) 
LSS Frequency Percent 
Absent 51 83.6 
Present 10 16.3 
Total 61 100.0 
 
The majority of patients in this study were belong to alcoholic 
cirrhosis which  constitutes of about 60.7%.  , which is followed by 
Hepatitis B , 19.7% 
 
TABLE 9: ETIOLGY OF CIRRHOSIS  
 
 Etiology Frequency Percent
Valid 
Percent 
Cumulative 
Percent 
AIH 1 1.6 1.6 1.6
 ALC 37 60.7 60.7 62.3
 CRYP 6 9.8 9.8 72.1
 HBV 12 19.7 19.7 91.8
 HCV 5 8.2 8.2 100.0
 Total 61 100.0 100.0  
 
Variables associated with the presence of oesophageal varices on 
univariate  analysis  Eleven variables considered relevant to the presence of 
oesophageal varices  were tested using univariate analysis. Results are 
summarized in Table 5.  
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TABLE  10 : DESCRIPTIVE STATISTICS OF VARIABLES  
ASSOCIATED WITH PRESENCE OF ESOPHAGEAL VARICES 
 
Variables N Minimum Maximum Mean Std. Deviation
(DD) DISEASE 
DURATION 
61 20 240 85.98 46.982
Platelets 61 70000 415000 168049.18 78614.974
Bilirubin 61 .8 11.2 2.495 1.6767
SAAG 61 .9 1.6 1.231 .1478
PLT/SLD RATIO 61 236.92 3365.38 1367.5889 739.54224
SPLEEN SIZE 61 9.0 26.0 13.264 3.3378
(PV ) PORTAL 
VEIN DIAMETER 
61 8 18 12.26 2.352
(SV) SPLENIC 
VEIN DIAMETER 
61 7 12 8.54 1.478
Coloumn 61 1 4 3.03 .983
Length 61 1 12 8.02 2.102
NH4 61 38 108 72.49 19.607
 
PLD/SLD – Platelet- Spleen ratio 
 
Univariate  analysis revealed that platelet count, spleen width, portal 
diameter  CTP grade were significantly associated with the presence of 
oesophageal  varices 
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VARIABLES PREDICTING PRESENCE OF ESOPHAGEAL 
VARICES (EV) 
 
Platelet count of 1,50,000 /mm3   was considered  as 
thrombocytopenia and it  correlate well with the presence of esophageal 
varices. 
 
      TABLE 11 : PLATELET COUNT PREDICTING  EV  
 
Platelets 
GRADE 
Total small large 
 <1,50,000 7 20 27
> 1,50,000 17 17 34
Total 24 37 61
            P values 0.05 
 
A Platelet / spleen ratio of about 909 was chosen as a cut off value 
according to  previous studies . 
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TABLE 12 : PLATELET/ SPLEEN RATIO PREDICTS EV   
 
PLD/SLD 
EV 
Total small large 
< 909 21 17 38
>909 3 20 23
Total 24 37 61
P value  .001 
 
Spleen size is another important predictor of esophageal varices. 
Spleen size of  more than 11cms was chosen as acut off value. 
 
TABLE 13 : Spleen size as a predictor of  EV  
 
SPLEEN 
GRADE 
Total small large 
 >11 cm 9 30 39
<11 cm 15 7 22
Total 24 37 61
P value .001 
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TABLE 14 : Portal vein size  size correlating with EV  presence  
 
Portal vein  
  
Grade Total 
Absent Small Large   
 < 11 mm 19 7 11 37 
  >11 mm 5 4 15 24 
P- value  0.02  
 
TABLE 15 : CTP grade correlates with the presence of varices. 
 
EV 
  
  CTP Total 
  A B C   
 Absent Count 9 6 9 24
  Small Count 2 7 2 11
  Large Count 3 5 18 26
 
P value  0.006 
Normal  Venous  ammonia  level  is  between 10–35 μmol/L.Values 
more than 35 was considered abnormal  
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TABLE 16  : VENOUS AMMONIA LEVEL  
 
NH3 
EV TOTAL 
present Absent 
 >35mmol 33 17 50
<35 mmol 4 7 11
Total 24 37 61
P value < 0.05 
 
Data showing Association of non Invasive markers with collaterals other 
then EV  
Variable GV 
(P value) 
(LSS) 
P value 
PHG 
(P value) 
NH4 0.7 0.4 0.1 
Spleen size  0.2 0.2 0.1 
Platelet count  0.04 0.02 0.02 
 
The above data shows  only platelet count has got association with 
collaterals other then EV 
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DISCUSSION 
 
 With the growing number of chronic liver disease in the world , the 
likelyhood  of patients undergoing  variceal screeing by endoscopy will 
also increase. Non  invasive screening for identifying patients with high 
risk varices will definetly  of help by means of reducing the cost and 
improve patient’s tolerability   Studies conducted on non invasive predictor 
of varices (Table -17) lack uniformity  in their structure . The conclusion 
from most of these studies is that by selecting patients for endoscopic 
screening based on a few laboratory and/or  ultrasonographic variables 
(usually the platelet count and the diameter of the  portal vein), an 
appreciable number of endoscopies may be avoided, while keeping the rate 
of undiagnosed varices, which are at risk of bleeding, acceptably low 
.However, the predictive accuracy of such noninvasive  markers is still 
considered to be unsatisfactory, and none of them has been  recommended 
for use in clinical practice so far.45 
 
Practice guidelines for the treatment of portal hypertension  
recommended  endoscopic screening of patients with cirrhosis for varices, 
and treatment of  patients with medium or large varices to prevent 
bleeding. These  recommendations imply a considerable burden of 
endoscopies and related costs; patients repeatedly undergo an unpleasant 
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procedure, even though up to 50% of them may still not have developed 
esophageal varices 10  years after the diagnosis of cirrhosis. 
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Cirrhosis is the most advanced form of liver disease and variceal 
hemorrhage is  one of its lethal complications. Over half of the patients 
with  cirrhosis will develop varices. The risk of bleeding once OV formed 
is 20% to  35% within 2 years.49 The reported mortality rate from first 
episode of variceal bleeding is 17% to 57%. Of those who survive the 
initial episode of bleeding  and who do not receive active treatment, the 
risk of recurrent bleeding is approximately 66% and usually occurs within 
6 months of the initial bleeding  episode.(50)  
 
Because cirrhotic patients with large esophageal varices are at a high 
risk for  bleeding, preventive efforts have concentrated on identifying 
cirrhotic patients  with large varices. 51     In 1997, The American    Collage 
of Gastroenterology  (ACG) recommended screening endoscopy for cases 
with established cirrhosis  who were    candidates for medical therapy 52 .  
AASLD  recommended  screening endoscopy for varices  and to be in 
particular routine in child class B  and C patients, but in child class A to be 
limited to patients with evidence of  portal hypertension53  
 
It was estimated that 100 screening endoscopy need to be preformed 
to  prevent 1-2 cases of variceal bleeding .Therefore, identification of 
clinical  features that can accurately predict esophageal varices and help 
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identifying  patients at greatest risk is important    to improve the yield and 
cost-  effectiveness of endoscopic screening. 
 
Bleeding occurs in significant proportion of patients with severe 
PHG which  accounts for most non variceal bleeding episodes in patients 
with cirrhosis and  portal hypertension. PHG bleeding is a serious 
complication, which is usually  chronic and insidious but occasionally 
massive and life – threatening54 .Overt  hemorrhage from the gastric 
mucosa occurred in 60% of patients with severe  PHG with a cumulative 
risk of bleeding of 75% over a 5 –year follow –up  period 55 
 
In the present study, the parameters linked to portal hypertension 
(platelet  count, portal vein diameter, splenic diameter and platelet 
count/spleen ratio),  were associated with the presence of  esophageal 
varices. The issue of identifying patients with EV at risk of bleeding by 
non  invasive means is relevant and has been addressed in several recent  
studies  67, but only few Indian studies compared the above parameters as a  
prediction of  gastric varices and other large porto systemic collaterals. 
This  study  is an  attempt to achieve this goal  
   
Commenting on the results, our data in cirrhotic patients  support a 
good  association between blood NH4 levels and EV presence. The  blood 
ammonia determination suffers from some limits in its measurements. In  
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fact, the collection, handling, storage, and analysis of blood samples are all  
potential sources of error.  Recommendations has to be made on the 
collection and processing of blood samples, for it is bystandardization and 
rigid  adherence to these techniques that the reliability of the test results 
will be  improved.  
 
Our data  in this study agree with the body of present knowledge.  
When comparing the performance of blood ammonia with the PLTs/SLD 
ratio (56) the only marker contextually studied, we found a not so much 
dissimilar reliability. The advantages of the PLTs/SLD ratio are evident 
because they do not suffer from external confounding factors. The 
disadvantages are consistent with the fact that thrombocytemia is sometime 
related to the auto-antibodies presence that turns out in falsely low count of 
PLTs. Indeed, the opposite, falsely high count of PLTs, could be detected 
in patients suffering from liver cirrhosis with hepatocarcinoma. 
 
The key point is not whether to recommend endoscopy or not but 
when to undergo it. Decision about the optimal intervals for surveillance 
mainly to detect large varices depends on what proportion of patients that 
bleeds before starting prophylactic treatment we are willing to accept. 
According to this study  patients with high levels of NH4 should undergo 
endoscopy faster81. 
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In determining portal hypertension,mechanisms potentially 
reversible are involved, i.e., contractility of sinusoidallining cells, systemic 
mediators of arteriolar resistance, production ofendothelins or nitric oxide, 
and swelling of hepatocytes 57 However, other irreversible factors such as 
tissue fibrosis and regeneration increase resistance in the sinusoids and 
terminal portal venules, playing a key role. Even though PHG is 
recognized as a clinical entity associated to portal hypertension, its 
significance has not yet been elucidated 30 
 
Our observation that blood NH4 levels predicted both ascites and 
collaterals presence is intriguing, reinforcing the concept of a common 
origin. Data from long follow-up of patients suffering from compensated 
cirrhosis B show that poor hepatic reserve and severity of portal 
hypertension significantly correlate 59 At the same manner, measurements 
of portal pressure provide unique prognostic information for predicting 
portal hypertensive-related bleeding and mortality in patients with 
alcoholic cirrhosis  60 also in patients without clear presence of EV (31)  
 
High values of blood NH4 are important because they point out an 
incoming liver decompesation; in fact, less blood reaches the liver, 
diminishing thus the hepatic reserve. Portal-systemic collaterals provide a 
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pathophysiological route to decompress the hypertensive portal system. 
Despite this, the vascular resistance of the collateral bed is still greater than 
the resistance of the liver, and portal pressure does not decrease 62 .What is 
more, ammonium compounds increase vascular tone by causing influx of 
extracellular calcium through the voltage-dependent calcium channel and 
intracellular alkalinisation 63 
 
While determining indirect evidence of portosystemic shunts 
presence, some laboratory parameters have already been proposed, i.e., 
Serum Bile Acids (SBA) and Indocyanine Green Clearance (IGC). Both 
are reliable, butblood ammonia level is a higher sensitive and specific 
parameter 64 
 
Colonoscopy was not offered to any patient as none of the patients 
have symptoms of portal hypertensive colopathy. Although detection of 
other portosystemic collaterals besides EV improves the specificity of 
NH4, it is barely important in clinical practice as prophylactic remedies are 
not warranted.  
 
Platelet count  
 
Thrombocytopenia in patients with cirrhosis has historically been 
attributed to  hypersplenism due to portal hypertension. Several studies 
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suggest that platelet  count may predict the presence of EV in patients with 
cirrhosis .  However, the discriminating threshold for the presence of 
varices varies widely,  ranging between 68,000 and 160,000/mm3  65 . The 
sensitivities for  thrombocytopenia fluctuate from 62% to 100%, and the 
specificities range from  18% to 77% 66  .Our data suggest that the 
multivariate analysis failed to show  any significant difference between 
thrombocytopenia and the risk of EV. In  addition, platelet count might not 
be an ideal predictor of the presence of EV in  HBV-related cirrhosis. A 
possible explanation is that other factors, such as  suppressive effects of 
viruses on bone marrow and antibody-mediated  destruction of platelets, 
may play a more important role in HBV-related  cirrhosis than that in 
alcohol cirrhosis, in addition to decreased thrombopoeitin  
and interleukin-11 67 .  
 
STUDIES ON PLATELET COUNT 
 
According  to Zaman et al ,  Platelet count <88,000 was the only 
parameter  identified by univariate/multivariate analysis (p < 0.05) as 
associated with the  presence of large esophageal varices68 
 
Thomopoulous et al in his study ,  Seventeen variables considered 
relevant to  the prevalence of oesophageal varices . Oesophageal varices 
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were present in 92  patients (50%), and large varices in 33 patients 
(17.9%).69 
 
Factors independently associated with the presence of large 
oesophageal varices on multivariate analysis were platelet count, size of 
spleen and presence of ascites by ultrasound.  
 
 
In Chalasani et at 70 , a study on three hundred and fourty patients , 
the  prevalence of large esophageal varices was 20%. On multivariate 
analysis,  splenomegaly ,detected by computed tomographic scan (odds 
ratio: 4.3; 95%  confidence interval: 1.6-11.5) or by physical examination 
(odds ratio: 2.0; 95%  confidence interval: 1.1-3.8), and low platelet count 
were independent  predictors of large esophageal varices. On the basis of 
these variables, cirrhotics  were stratified into high- and low-risk groups for 
the presence of large  esophageal varices. Patients with a platelet count of  
 > 88,000/mm3 (median  value) and no splenomegaly by physical 
examination had a risk of large  esophageal varices of 7.2%. Those with 
splenomegaly or platelet count < 88,000/mm3 had a risk of large 
esophageal varices of 28% (p < 0.0001).  
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SPLENOMEGALY  
 
Splenomegaly is recognized as one of the diagnostic signs of 
cirrhosis and  portal hypertension. Our data showed that spleen width 
measured by  ultrasonography was an independent predictor for the 
presence of varices. 
 
Dib N, et al71 identified  non invasive diagnosis of large esophageal 
varices  because of prognostic and economic issues. Indirect echographic 
markers of  portal hypertension and esophageal varices (ascites, portal vein 
diameter > or =  13 mm, spleen length, maximal and mean velocimetry of 
portal vein flow,  respectively < 20 cm/s and < 12 cm/s) could be useful. 
Among this parameters,  spleen length is an independent predictive marker 
of esophageal varices  
 
In Sharma et al 72 study,  101 patients (median age 45; range 15-74 
years; 87  male; Child-Pugh class: A 18, B 31, C 52), 46 had LEVx. On 
univariate  analysis, five variables  were significantly associated with the 
presence of LEVx.  
 
These included pallor (P = 0.026), palpable spleen (P = 0.009), 
platelet count (P  < 0.002), total leukocyte count (P  <  0.0004) and liver 
span on ultrasound (P =  0.031). On multivariate analysis, two of these 
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parameters, namely low platelet  count and presence of palpable spleen, 
were found to be independent predictors  of the presence of LEVx. 
 
In Jeon sw et al study 73  variables associated with the presence of 
esophageal  varices on univariate analysis were serum albumin, total 
bilirubin, prothrombin  time and platelet count ( P < 0.05).  On multivariate 
analysis, independent  variables were platelet count (odds ratio (OR) 0.922; 
95% confidence interval  (CI), 0.86-0.99), diameter of spleen (OR 5.4; 
95% CI, 1.63-17.88) and platelet  count/spleen diameter ratio (OR 1.007; 
95% CI, 1.01-1.02). The optimal critical  value for the diameter of spleen 
was 11 cm. The sensitivity and specificity with  this value were 84% and 
63%, respectively 
 
Platelet count/ spleen ratio 
 
With the best cut-off value of 909   , the platelet count/spleen width 
ratio yielded a low diagnostic accuracy of 60.3%, which suggests that it is 
not an ideal predictor for EV. 
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In a study conducted by Schwarzenberger   et al 74  of the 137 
patients with 87  (63.5%) men and a mean age of 56 years,  seventy-six 
(55%) patients had  esophageal varices.Using a platelet count/spleen 
diameter ratio with a cut-off  value of 909, yielded a negative predictive 
value of only 73% and a positive  predictive value of 74%. 
 
Giannini E et al 75 conducted a study in  121 patients,  
ultrasonographic measurement  of spleen bipolar diameter. Platelet 
count/spleen diameter ratio were calculated for all patients. The prevalence 
rates of OV were 61% and 58% in the first and second groups of patients, 
respectively.the platelet count/spleen diameter ratio was the only parameter 
which was independently associated with the presence of OV in a 
multivariate analysis. A platelet count/spleen diameter ratio cut off  value 
of 909 had 100% negative predictive value for a diagnosis of OV. This  
result was reproduced in the second group of patients as well as in patients 
with compensated disease. In a cost-benefit analysis, screening cirrhotic 
patients according to the "platelet count/spleen diameter ratio strategy" 
was far more cost effective compared with the "scope all strategy”. 
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In  Baig WW et al 76 study,  the platelet count to spleen diameter 
ratio had the  highest accuracy among the three parameters. By applying 
receiver operating  characteristic curves, a platelet count to spleen diameter 
ratio cut-off value of  1014 was obtained, which gave positive and negative 
predictive values of  95.4% and 95.1%, respectively. 
 
In Zaman et al study77 , A total of 218 cirrhotic patients underwent 
screening  endoscopy for EV. Platelet count/spleen diameter ratio  was 
assessed in all  patients and its diagnostic accuracy was calculated. 
Prevalence of EV was  54.1%. The platelet count/spleen diameter ratio had 
86.0% (95% CI, 80.7- 90.4%) diagnostic accuracy for EV, which was 
significantly greater as  compared with either accuracy of platelet count 
alone (83.6%, 95% CI 78.0- 88.3%, P= 0.038) or spleen diameter alone 
(80.2%, 95% CI 74.3-85.3%, P=  0.018). The 909 cutoff had 91.5% 
sensitivity (95% CI 85.0-95.9%), 67.0%  specificity (95% CI 56.9-76.1%), 
76.6% positive predictive value, 87.0%  negative predictive value, 2.77 
positive likelihood ratio, and 0.13 negative  likelihood ratio for the 
diagnosis of EV. Accuracy of the platelet count/spleen  diameter ratio was 
maintained for both severity and etiology of disease  subgroups. 
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Studies  on  other non invasive markers 
 
According to Bressler B et al 78 , a total of 235 patients with chronic 
liver disease, including 79 patients with PBC,7 patients with PSC , 104 
patients with chronic viral hepatitis, and 45 with non-alcoholic cirrhosis of 
differing aetiologies, oesophageal varices were detected in 26 (30%) of the 
PBC/PSC group, 38 (37%) of the viral hepatitis group, and 21 (47%) of the 
"other" group. Applying multiple logistic regression analysis to the data in 
the group with PBC/PSC,  platelets <200,000/mm3 (odds ratio (OR) 5.85 
(95% confidence interval (CI)  1.79-19.23)), albumin <40 g/l (OR 6.02 
(95% CI 1.78-20.41)), and serum bilirubin >20 micromol/l (OR 3.66 (95% 
CI 1.07-12.47)) were shown to be independent risk factors for oesophageal 
varices. The study conclude patients  with a platelet count <200,000/mm3, 
an albumin level <40 g/l, and a bilirubin  level >20 micromol/l should be 
screened for oesophageal varices. 
 
Ng fh79 on prediction of esophageal varices conclude that 
Endoscopic screening for EGV was not necessary until 
thrombocytopenia or ascites occurred.  In their study, ninety-two 
patients were recruited. From all patients studied, the  size of palpable 
spleen, liver chemistry value, platelet count, prothrombin time,  diameter of 
main portal vein and splenic length . Low platelet count and  presence of 
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ascites were the significant independent predictors for high-grade  EGV 
(concordance rate 0.83). The optimal critical value for the platelet count  
was 150 x 10(9)/L. Of patients without thrombocytopenia and ascites, 37% 
had  low-grade EGV but none had high-grade EGV, whereas 38 and 35% 
of patients  with thrombocytopenia or ascites had low and high-grade EGV, 
respectively.  Therefore, this predictive model for high-grade varices had a 
positive and  negative predictive value of 35 and 100%, respectively. 
 
In Madhotra et al study80 , independent predictors of large varices 
were  thrombocytopenia ( p = 0.02) and splenomegaly ( p = 0.04) seen 
using imaging.  A platelet count of less than 68,000/mm 3 had the highest 
discriminative value  for large EV with a sensitivity of 71% and a 
specificity of 73%. Splenomegaly  had sensitivity and specificity of 75% 
and 58%, respectively None of the parameters , namely platelet count , 
spleen size , platelet /spleen size ratio and venous ammonia level correlate 
with the presence of  gastric varices. Similarly none of these parameters 
correlate with the large porto systemic shunts . 
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CONCLUSION 
 
1. Identifying  high ammonia  levels in cirrhotic patients is a good non 
invasive  marker of esophageal varices 
 
2. Among the non invasive markers studied, only  platelet count 
predicts Gastric varices, portal hypertensive gastropathy and  large 
spontaneous shunts.  
 
3. Spleen size & portal vein size are sonographic  markers of large 
esophageal varices  
 
4. Simple platelet / spleen ratio is a useful predictor of large esophageal 
varices 
 
5. Non invasive predictors are safe, acceptable, patient friendly method 
of identifying esophageal varices 
 
6. Non Invasive markers are helpful in selecting patients with low 
probability of esophageal varices in whom upper GI endoscopy may 
not be needed.  
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 PROFORMA 
Name  
Age  
Sex  
Occupation  
Address  
DDHD No 
IP No 
VOGD No 
Occupation  
Disease Duration  
SYMPTOMS 
Abdominal distension 
Leg swelling 
Jaundice 
Altered sensorium 
Blood vomiting 
Malena 
Weight loss 
PAST HISTORY 
Blood vomiting 
Malena 
Jaundice  
Blood transfusions 
Tattooing 
Ear piercing 
Jaundice 
Diabetes  
Hypertension  
Other co morbidities – if any  
PERSONAL HISTORY 
Smoking                                  Amount                               Duration 
Alcohol                                   Amount                               Duration 
Marital status  
Children 
Siblings  
I.V Drug abuse 
Lactulose  
Menstrual history  
 
 
  
Examination :  
Ht : cms  Wt: Kgs BMI: 
Pallor: Icterus: Cyanosis: 
Clubbing: Pedal edema: LN: 
Spider angioma: Scartch marks:  
Palmar erythema: Parotid enlargement: KF ring  
Gyneacomastia: Asterxis: RR : 
JVP: PR:  BP: 
 
Abdomen examination : 
ABD Distension: Veins: 
Ascites Liver span: Spleen 
Per rectal Ex : 
CVS: 
RS: 
CNS : Grade of encephalopathy: 
 
Investigation: 
Hb: TC:  DC 
ESR :  Platelet count:  
BT: CT:  P.Smear: 
B.Ures: B.Sugar S.Cr. 
Prothrombin time: 
LFT: 
T.Bil: Direct: Indirect: 
SGPT: SGOT SAP: 
T.Protein: S.Albumin: 
Ascitic fluid : 
Protein: Albumin: Cell count: 
Cytology SAAG : CTP score: 
Hbs AG: HCV: 
S.Ceruloplasmin: 
ANA: Anti Sm Ab: 
Anti LKM Ab: AMA: Others  
Venous Ammonia  
 
ULTRASOUND: 
Liver size  Texture : Nodule: 
Spleen vein: PV flow: 
Splenic vein SV flow: 
Collaterals  Others: 
  
UPPER GI SCOPY 
ESOPHAGEAL VARICES: 
Grade: No.of columns: Length: 
Red signs: Gastric varices: PHG: 
 
COLONOSCOPY: 
Rectal Varices: Colopathy: 
Liver biopsy: 
Others  
  
